JAMA NetworkEfficacy of Preoperative mFOLFIRINOX vs. mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

The 18-month OS rates in this trial were:

• 66.7% for neoadjuvant mFOLFIRINOX
• 47.3% for neoadjuvant mFOLFIRINOX and hypofractionated radiotherapy
• 87.5% for mFOLFIRINOX followed by pancreatectomy
• 78.9% for mFOLFIRINOX plus radiotherapy followed by pancreatectomy

The authors state these results “suggest that mFOLFIRINOX represents a reference neoadjuvant treatment regimen for borderline resectable pancreatic cancer; however, the role of radiotherapy in this setting remains undefined.”